MagForce Company Profile
Business Description
MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company's proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator(TM) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries
| First Quotation | September 20, 2007 |
| Accounting standard | German statutory accounting (HBG) |
| Fiscal year end | December 31 |
| Executive Board | Prof. Dr. Hoda Tawfik, Christian von Volkmann |
| Supervisory Board | Norbert Neef (Chairman), Dr. Jan zur Hausen, Bernd Förtsch |
Share trading information | |
| ISIN | DE000A0HGQF5 |
| German Securities Identification Number (WKN) | A0HGQF |
| Ticker Symbol | MF6 |
| Market Segment | Entry Standard |
| Stock Class | no-par value shares |
| Equity Capital | 23,922,711 Euro |
| Outstanding Share | 23,922,711 shares |
| Shareholding Structure | Avalon Capital One GmbH: 37.0% Nanostart AG: 10.8% Management: 0.7% Freefloat: 51.5% |
| Deutsche Börse Listing Partner and Specialist, Applicant | Steubing AG |
| Designated Sponsor | KochBank |
| Location | Max-Planck-Str 3, 12489 Berlin |